2020
DOI: 10.21037/tau-20-979
|View full text |Cite
|
Sign up to set email alerts
|

Novel mutations in response to vitamin B6 in primary hyperoxaluria type 1 after only kidney transplantation: a case report

Abstract: Recently, the mainstream curative treatment for primary hyperoxaluria type 1 (PH1) is combined liver and kidney transplantation, and only kidney transplantation is considered ineffective for most PH1 patients. Furthermore, vitamin B6 (B6) is the only permitted drug available for treatment. However, except for specific mutations such as G170R and F152I in gene AGXT, data of B6 effect on other mutations are lacking. Insufficient research has evaluated the efficacy of the combination of kidney transplantation and… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 16 publications
0
3
0
Order By: Relevance
“…Currently, conservative treatments are unsatisfactory for the treatment of DGF secondary to PH [ 26 ]. Three patients with PH reported a reversal of the continuous increase in creatinine by oral vitamin B6 therapy [ 5 , 10 , 18 ]. This may be due to the fact that some patients with specific mutations in AGXT are sensitive to B6 treatment [ 18 , 27 ].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Currently, conservative treatments are unsatisfactory for the treatment of DGF secondary to PH [ 26 ]. Three patients with PH reported a reversal of the continuous increase in creatinine by oral vitamin B6 therapy [ 5 , 10 , 18 ]. This may be due to the fact that some patients with specific mutations in AGXT are sensitive to B6 treatment [ 18 , 27 ].…”
Section: Discussionmentioning
confidence: 99%
“…Three patients with PH reported a reversal of the continuous increase in creatinine by oral vitamin B6 therapy [ 5 , 10 , 18 ]. This may be due to the fact that some patients with specific mutations in AGXT are sensitive to B6 treatment [ 18 , 27 ]. To the best of our knowledge, this is the first case to report the plasma oxalate concentration of pre-continuous and post-continuous renal replacement therapy (72 h) in a patient with PH diagnosed after kidney transplantation.…”
Section: Discussionmentioning
confidence: 99%
“…Precious metal catalysts possess high catalytic activity in both ORR and OER processes, and thus can be considered as the potential candidate of air cathodes for flexible ZABs. [ 92–95 ]…”
Section: The Cathodes Of Flexible Zabsmentioning
confidence: 99%